NovaBay Pharmaceuticals Launches Avenova® Direct on Amazon.com
June 10 2019 - 6:50AM
Business Wire
Original formulation of Avenova® for the
management of bacterial dry eye is now available at an affordable
price without a prescription
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
biopharmaceutical company focusing on commercializing Avenova® for
the domestic eye care market, announces that Avenova® Direct is
available at affordable pricing and without a prescription on
Amazon.com through the Company’s new direct-to-consumer online
channel. Avenova, the leading lid and lash spray, is designed for
the removal of bacteria and debris on and around the eyelid margin
that contribute to bacterial eye infections, which represent
approximately 85% of the dry eye market. The Avenova Direct page on
Amazon.com is available here.
“Patients throughout the U.S. can now purchase Avenova Direct
without a prescription in Avenova’s original prescription
formulation,” said Justin Hall, Interim President and CEO of
NovaBay. “For many years, the bacterial microorganisms that are the
underlying cause of the vast majority of dry eye cases were almost
impossible to manage. Avenova Direct effectively manages bacterial
dry eye through our pure 0.1% hypochlorous acid formulation in
saline, which is free from bleach, surfactants and other
impurities. I firmly believe this is the best product available for
the topical treatment of these chronic ocular bacterial
infections.
“While prescription Avenova continues to be available through
retail pharmacies and direct in-office sales by certain eye care
specialists, patients and physicians have asked for greater
accessibility to the product. In response, we are launching our new
U.S. direct-to-consumer channel, which is a significant step in
ensuring easy access at an affordable price,” he added. “This
direct channel further provides NovaBay with set pricing that is
not impacted by the current health plan reimbursement
environment.”
Avenova Direct is available from Amazon in the U.S. in a 20ml
size for $29.99. Avenova is gentle, refreshing and soothing for
everyday eyelid and eyelash use.
The launch of NovaBay’s direct-to-consumer channel is supported
by Avenova’s existing brand awareness campaign. In addition, the
Company is conducting a comprehensive online promotional strategy
that includes search engine optimization, Google Ads and Amazon
promotions using searchable keywords, Facebook lead ads and social
media marketing targeting influencers, and email campaigns focused
on ophthalmologists, optometrists and current and former Avenova
patients.
About Avenova®
Avenova is an eye care product formulated with our proprietary,
stable and pure form of hypochlorous acid. Avenova is designed for
removal of the microorganisms and debris that contribute to
conditions such as meibomian gland dysfunction, dry eye and
blepharitis. Avenova is marketed to optometrists and
ophthalmologists throughout the U.S. by NovaBay’s direct salesforce
and available online through Amazon.com.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Forward-Looking Statements
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding our future listing on the NYSE,
our ability to continue as a going concern, and generally the
company’s expected future financial results. These statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results or achievements to be materially
different and adverse from those expressed in or implied by the
forward-looking statements. Factors that might cause or contribute
to such differences include, but are not limited to, risks and
uncertainties relating to our ability to remain a publicly listed
company, maintain the support of our majority shareholders, and
ability to adhere to our approved NYSE compliance plan. Other risks
relating to NovaBay’s business, including risks that could cause
results to differ materially from those projected in the
forward-looking statements in this press release, are detailed in
NovaBay’s latest Form 10-Q/K filings with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay informed on
NovaBay’s progress:Like us
on FacebookFollow us on TwitterConnect with
NovaBay on LinkedInVisit NovaBay’s Website
Avenova Purchasing
InformationFor NovaBay Avenova purchasing
information:Please call 800-890-0329 or
email sales@avenova.com.www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190610005123/en/
NovaBay ContactJustin
HallInterim President and Chief Executive
Officer510-899-8800jhall@novabay.com
Investor ContactLHA Investor
RelationsJody Cain310-691-7100jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024